{'fraction_non_alphanumeric': 0.03975799481417459, 'fraction_numerical': 0.02679343128781331, 'mean_word_length': 4.819095477386934, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Molecular Docking Studies and in silico ADMET Screening of Indazole
Scaffolds as VEGFR and Enoyl-ACP (CoA) Reductase Inhibitors

Lung cancer is expected to account for 11.4 % of the cancer burden in 2020, with an estimated 2.2
million new cases diagnosed and 1.8 million deaths occurring. Non-small-cell lung cancer accounted
for approximately 85% of newly diagnosed lung cancer cases. In non-small cell lung cancer and
tuberculosis level of vascular endothelial growth factor was found to be elevated, which induces
angiogenesis. In this study molecular docking analysis along with pharmacokinetic/ADMET and drug
likeness prediction were carried out to evaluate the newly designed indazole scaffolds as potent VEGFR
and Enoyl-ACP (CoA) reductase enzyme inhibitors. Out of 11 screened compounds, two compounds
having good scores (-7.72 and -7.54 kcal/mol) emerged as effective and potent VEGFR-2 inhibitors
and three compounds showed highest binding affinities (-8.30, -7.76, -7.62 kcal/mol) with
Enoyl-ACP. This study reveals that, newly designed indazole compounds could be the potential drug
of choice against non-small cell lung cancer and tuberculosis.